I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting 2021-10-05 20:00
I-Mab Announces Upcoming Participation at October Conferences 2021-10-01 20:00
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab 2021-09-30 20:00
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors 2021-09-28 20:00
I-Mab Added to FTSE ESG Index Series 2021-09-13 20:00
I-Mab Added to FTSE Russell Global Equity Index Series 2021-09-02 20:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 2021-08-31 18:00
I-Mab Announces Upcoming Participation at September Conferences 2021-08-30 20:00
I-Mab Announces Establishment of Environmental, Social and Governance Committee 2021-08-19 19:00
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021 2021-08-17 20:00
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease 2021-07-30 20:00
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million 2021-07-29 20:00
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China 2021-07-28 19:15
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange 2021-07-27 20:35
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms 2021-07-09 20:00
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio 2021-07-01 20:00
I-Mab Honored with Top Rankings by Institutional Investor 2021-06-30 20:00
I-Mab Announces Upcoming Participation at July Conference 2021-06-29 20:00
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus 2021-06-25 20:00
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board 2021-06-21 20:00
1 3 4 5 6 7 9